Cancer ASEA (@CancerASEA) / Twitter
Salomon Manier
Pr Salomon MANIER - Auteur | Edimark
PDF) Deregulation and Targeting of TP53 Pathway in Multiple Myeloma
GLS1 dependency in MYC over-expressing multiple myeloma: New target for therapy? - ecancer
☎️ Contacts du Dr Salomon Manier, Hematologue à Lille 59000
ide-cel and neurotoxicity | Int'l Myeloma Foundation
L'ARC soutient les recherches menées à l'IRCL - IRCL
Massimo Corsaro (@Massimo_Pfizer) / Twitter
Salomon Manier's research works | Centre Hospitalier Universitaire de Nancy, Laxou (CHU Nancy) and other places
Primary refractory young myeloma: a difficult clinical situation - YouTube
Myeloma Crowd Radio: Irene Ghobrial, MD & Salomon Manier, MD, PhD, Dana Farber 09/27 by HealthTree Podcast for MM | Health
Antibody-drug Conjugates in Relapsed/Refractory Multiple Myeloma: from Bench to Bedside - Springer Healthcare IME
Pr Salomon MANIER - Auteur | Edimark
Pr Salomon MANIER - Auteur | Edimark
GLS1 dependency in MYC over-expressing multiple myeloma: New target for therapy? - ecancer
IACH on Twitter: "Join us TODAY at 2pm Eastern Time (Atlanta), 8pm CET (Paris) for live news from #ASH21 with Dr. Salomon Manier and @Mohty_EBMT Register Free here: https://t.co/bdQmP2b0TS https://t.co/oYQD70BBZf" / Twitter
Dr. Tarek Mouhieddine, MD – New York, NY | Internal Medicine
Next generation sequencing identifies smoldering multiple myeloma patients with a high risk of disease progression - ecancer
Salomon Manier - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115; | 人才画像- AMiner
